Exploring the Immune Response in Community Acquired Pneumonia
Innate Immunity During Community Acquired Pneumonia: A Translational Approach
This study is trying to see how certain immune cells behave in people with community-acquired pneumonia and those who may develop severe breathing problems, by looking at samples from their blood and lungs.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Tours Academic / other |
| Locations | 4 sites (Limoges and 3 other locations) |
| Trial ID | NCT03379207 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of non-conventional T cells in patients with community-acquired pneumonia (CAP) and those progressing to Acute Respiratory Distress Syndrome (ARDS). It aims to include 100 participants diagnosed with CAP admitted to the ICU and 50 control participants without pneumonia. The study will analyze blood samples, tracheal aspirates, and broncho-alveolar lavage fluid to assess the presence and functionality of these immune cells. The findings could provide insights into the immune dysregulation associated with severe pneumonia and ARDS.
Who should consider this trial
Good fit: Ideal candidates include patients admitted to the ICU with a diagnosis of community-acquired pneumonia.
Not a fit: Patients with advanced comorbidities or those for whom treatment is limited within 5 days may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies to modulate immune responses in pneumonia and ARDS, potentially reducing mortality rates.
How similar studies have performed: While studies on non-conventional T cells in other diseases have shown promise, this specific approach in pneumonia and ARDS is novel and untested in humans.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: "Pneumonia" group: * Admission to the Intensive Care Units or Pneumonia service of Tours University Hospital or Intensive Care Unit or Limoges University Hospital * Initial diagnosis of acute community-acquired pneumonia suggested by the presence of a cough, dirty sputum, chest pain and / or dyspnea (at least two criteria required), associated with the presence of a radiological or CT infiltrate initially * Patient for whom it is not envisaged, a priori, to limit treatment within 5 days following inclusion, for ethical reasons, due to age and advanced comorbidities, and / or a level of severity beyond all therapeutic possibilities. * Diagnosis of pneumonia done within 48 hours after admission to the hospital * Participant admitted to the hospital for less than 8 days "Control" group: * Admission to the Intensive Care Units of the University Hospital of Tours or Limoges University Hospital * Use of invasive mechanical ventilation for less than 48 hours * Predictable duration of invasive mechanical ventilation\> 48h * Participant admitted to the hospital for less than 8 days * Absence of pneumonia criteria (according to the criteria defined for the "Pneumonia" participant group) * Absence shock (defined by the need for vasopressor despite volume expansion ≥30mL/kg, associated with a blood lactate level ≥ 2mmol / L * Patient for whom it is not envisaged, a priori, to limit treatment within 5 days following inclusion, for ethical reasons, due to age and advanced comorbidities, and / or a level of severity beyond all therapeutic possibilities. Exclusion Criteria: * Participant under protection * Pregnant or lactating women
Where this trial is running
Limoges and 3 other locations
- University Hospital of LIMOGES — Limoges, France (Withdrawn)
- University Hospitakl of TOURS Département of Pneumonia — Tours, France (Not_yet_recruiting)
- University Hospital -Bretonneau - Intensive Care — Tours, France (Recruiting)
- University Hospital of Tours; INSERM CIC 1415 — Tours, France (Enrolling_by_invitation)
Study contacts
- Study coordinator: Youenn JOUAN, MD-PHD
- Email: youenn.jouan@gmail.com
- Phone: +33 247479861
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.